Summary of response, OS, and clonal evolution in refractory AA patients treated with second-line IST using ATG
| Reference . | N . | ATG first course . | ATG second course . | Response . | OS . | Clonal evolution . |
|---|---|---|---|---|---|---|
| Scheinberg et al18 | 27 | hATG + CSA | rATG + CSA | 33% | 60% at 3 y | 2 with −7, 1 with t(6;14), 1 with trisomy 6 |
| Scheinberg et al14 | 22 | hATG + CSA ± MMF or sirolimus | rATG + CSA ± MMF or sirolimus | 30% | 70% at d +1000 | 2 (MDS: +6, −7), 2 (AML) |
| Di Bona et al13 | 30 | hATG + CSA + G-CSF (until d 90) | rATG + CSA + G-CSF d +1-90 | 77% | 93% at d +914 | 2 (MDS), 1 (MGUS) |
| Tichelli et al42 | 25 | hATG + androgens + CSA after 1991 | hATG + androgens + CSA after 1991 | 64% | 55% at 10 y | NK |
| Marsh et al43 | 18 | hATG + androgens | rATG + androgens | 22% | NK | NK |
| Reference . | N . | ATG first course . | ATG second course . | Response . | OS . | Clonal evolution . |
|---|---|---|---|---|---|---|
| Scheinberg et al18 | 27 | hATG + CSA | rATG + CSA | 33% | 60% at 3 y | 2 with −7, 1 with t(6;14), 1 with trisomy 6 |
| Scheinberg et al14 | 22 | hATG + CSA ± MMF or sirolimus | rATG + CSA ± MMF or sirolimus | 30% | 70% at d +1000 | 2 (MDS: +6, −7), 2 (AML) |
| Di Bona et al13 | 30 | hATG + CSA + G-CSF (until d 90) | rATG + CSA + G-CSF d +1-90 | 77% | 93% at d +914 | 2 (MDS), 1 (MGUS) |
| Tichelli et al42 | 25 | hATG + androgens + CSA after 1991 | hATG + androgens + CSA after 1991 | 64% | 55% at 10 y | NK |
| Marsh et al43 | 18 | hATG + androgens | rATG + androgens | 22% | NK | NK |
hATG indicates horse ATG; rATG, rabbit ATG; MMF, mycophenolate mofetil; MGUS, monoclonal gammopathy of unknown significance; AML, acute myeloid leukemia; and NK, not known.